{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:29:24Z","timestamp":1740162564066,"version":"3.37.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100019518","name":"Eli Lilly Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.cjca.2017.02.013","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T08:15:22Z","timestamp":1488442522000},"page":"666-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?"],"prefix":"10.1016","volume":"33","author":[{"given":"Emily T.","family":"Brennan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tisha R.","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2017.02.013_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2017.02.013_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjca.2017.02.013_bib3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2017.02.013_bib4","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.02.013_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2017.02.013_bib6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.02.013_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11883-014-0475-4","article-title":"Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?","volume":"17","author":"Cornier","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2017.02.013_bib8","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/j.1755-5922.2011.00267.x","article-title":"Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge","volume":"30","author":"Fung","year":"2011","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2017.02.013_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2017.02.013_bib10","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2017.02.013_bib11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2017.02.013_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","article-title":"N-of-1 (single-patient) trials for statin-related myalgia","volume":"160","author":"Joy","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2017.02.013_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.02.013_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.02.013_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.02.013_bib16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14740338.2012.712959","article-title":"Statin drug interactions and related adverse reactions","volume":"11","author":"Bellosta","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cjca.2017.02.013_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jacl.2011.05.005","article-title":"Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia","volume":"5","author":"Harris","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2017.02.013_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","article-title":"Statin-associated muscle-related adverse effects: a case series of 354 patients","volume":"30","author":"Cham","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cjca.2017.02.013_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A\u00a0randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2017.02.013_bib20","first-page":"1499","article-title":"Management of dyslipidemia in primary care","volume":"19","author":"Alzahrani","year":"2003","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.02.013_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","article-title":"Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada","volume":"19","author":"Gitt","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cjca.2017.02.013_bib22","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","article-title":"Statin safety: an appraisal from the adverse event reporting system","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.02.013_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A\u00a0systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2017.02.013_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ahj.2014.01.014","article-title":"Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada","volume":"167","author":"Lu","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2017.02.013_bib25","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2017.02.013_bib26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/dia.2011.0287","article-title":"Diabetes empowerment, medication adherence and self-care behaviors in adults with type 2 diabetes","volume":"14","author":"Hernandez-Tejada","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.cjca.2017.02.013_bib27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2017.02.013_bib28","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X17300788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X17300788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T15:21:22Z","timestamp":1656775282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X17300788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0828282X17300788"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2017.02.013","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2017.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}